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ABSTRACT
Aim Randomised trials exploring remote ischaemic
preconditioning (RIPC) in patients undergoing coronary
artery bypass graft (CABG) surgery have yielded
conflicting data regarding potential cardiovascular and
renal protection, and are individually flawed by small
sample size.
Methods Three investigators independently searched
the MEDLINE, EMBASE and Cochrane databases to
identify randomised trials testing RIPC in patients
undergoing CABG.
Results Nine studies with 704 patients were included.
Standardised mean difference of troponin I and T release
showed a significant decrease (0.36 (95% CI 0.62
to 0.09)). This difference held true after excluding the
trials with cross-clamp fibrillation, the study with off-
pump CABG and studies using a flurane as anaesthetic
agent (0.41 (95% CI 0.69 to 0.12), 0.38 (95% CI
0.70 to 0.07) and 0.37 (95% CI 0.63 to 0.12),
respectively). A similar trend was also obtained for
patients with multivessel disease (0.41 (95% CI 0.73
to 0.08)). The trials evaluating postoperative creatinine
reported a non-significant reduction (0.02 (95% CI 0.09
to 0.13)). Moreover, the length of in-hospital stay was
not influenced by the kind of treatment (weighted mean
difference 0.27 (95% CI 0.24 to 0.79)).
Conclusion RIPC reduced the release of troponin in
patients undergoing CABG. Larger randomised trials are
needed to clarify the presence of a causal relationship
between RIPC-induced troponin release and clinical
adverse events.
INTRODUCTION
Remote ischaemic preconditioning (RIPC) consists
of protection of an organ from a sustained
ischaemic event obtained through the application
of brief sublethal ischaemia to another tissue.
Recently, this gained relevance in scientific debate,
thanks to its practical feasibility, limited costs and
potential benefits.
First discovered in animal models,1 it has been
rapidly translated to clinical arenas in different
settings such as, congenital heart defect correc-
tions,2 abdominal aneurysm repair3 and coronary
artery percutaneous or surgical revascularisation.4 5
This last context may be the most promising in
terms of new strategies for myocardial protection,
since the risk profile of patients referred for cardiac
surgery remains challenging, and established
evidence relates perioperative myocardial injury to
postoperative morbidity and mortality.6 7
Unfortunately, available data obtained from
randomised controlled trials (RCTs) on RIPC in
patients undergoing coronary artery bypass graft
(CABG) surgery are inconclusive. Some studies
outlined the efficacy of transient upper limb
ischaemic preconditioning to reduce serum tropo-
nins’ release after surgery,4 while similar protocols
failed to achieve statistically significant differences.
As discussed by Rahman et al,8 some studies may
be underpowered to exclude a lack of protection
by RIPC.
In the present review, we thus aimed to conduct
a comprehensive evaluation of current data to
further guide larger RIPC studies and future
implementation of new treatment strategies to
prevent myocardial damage or dysfunction in
patients undergoing CABG surgery.
METHODS
Data sources
The MEDLINE, EMBASE and Cochrane databases
were searched using terms such as ‘ischaemic
preconditioning’ or ‘remote ischaemic precondi-
tioning’, ‘surgical coronary revascularization’ or
‘coronary artery bypass graft surgery (CABG)’,
according to optimal search strategies.9
Reference lists of articles included were also
reviewed, and no language restriction was imposed.
All corresponding authors of shortlisted studies
were directly contacted for additional data, invited
to participate in data analysis and interpretation,
and were requested for suggestions for additional
studies.
Study selection
RCTs comparing troponin release after CABG of
patients assigned to RIPC or not were included,
while those comparing non-RIPC were excluded.
The outcomes of interest were release of cardiac
troponin I and T (defined as area under the curve, or
when available, data at 6, 24, 48 h and at peak),
values of creatinine (the highest creatinine valued
during follow-up; mg/dl) and length of in-hospital
stay.
Three investigators (GBZ, EC, FDA) indepen-
dently reviewed titles, abstracts and the full texts
as needed to determine whether studies met
inclusion criteria. Conflicts between reviewers were
resolved through re-review and discussion.
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Data extraction and quality assessment
Three authors (GBZ, EC, FDA) independently abstracted data on
study design, setting, RIPC protocols, assay of troponin used and
its upper limit of normality, number of patients with multivessel
disease (ie, three or more vessels protected with graft), protocols
of cardioplegia used, bypass and cross-clamp time.
Quality of included trials was explored according to Cochrane,
PRISMA and QUORUM statements;10 11 methods to obtain
sample size, selection bias (allocation and random sequence
generation), performance bias (blinding of participants and
personnel), detection bias (blinding of outcome assessment)
and attrition bias (incomplete outcome data) were assessed and
graphically described. Moreover, the Jadad Scale12 was also used
to appraise methodological quality of included studies.
Data synthesis and analysis
Random-effects models were exploited to compute standard
weighted mean difference (wmd) for troponin T and I separately
for creatinine and for length of in-hospital stay. Fixed-effects
models were also tested and their results reported only if different
from random effects. Troponin I values were analysed for patients
with multivessel disease only; standardised mean difference (smd)
was used to evaluate troponin release globally: RevMan 5 (The
Cochrane Collaboration, The Nordic Cochrane Centre, Copen-
hagen, Denmark) was used. Hypothesis testing for statistical
homogeneity was set at the two-tailed 0.10 level and based on the
Cochran Q test, with I2 values of 25%, 50% and 75% representing
mild, moderate and extensive statistical heterogeneity, respec-
tively. Funnel plot was explored to identify small-study bias.
RESULTS
Three hundred and three results were first appraised at abstract
level and 14 at full text level (figure 1); one was excluded because
298 records identified trough database 
searching
1 study was excluded because of
two consisting of two
retrospective RCTs.
5 records identified trough other sources
14 full texts assessed for elegibility
9 studies included in quantitative analysis (meta-analysis)
1 because evlauting creatine
kinase-MB
3 exploring non remote ischemic
preconditioning
Figure 1 Review profile.
Table 1 Main features of patients
Study
No. of
patients Age (years)
Multivessel
disease (%)
Ejection
fraction (%)
Hausenloy, 2007 57 67 83 53
Hong, 2010 130 65 e 56
Lucchinetti, 2012 55 60 70 50
Karuppasamy, 2011 54 67 70 50
Kottenberg, 2012 72 65 100 e
Rahman, 2010 162 63 100 e
Thielman, 2010 53 64 100 57
Venugopal, 2010 55 64 60 51
Wagner, 2010 66 67 80 53
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it consisted of a retrospective analysis of two RCTs;13 one
because it evaluated only creatinine kinase isoenzyme MB;14 and
three because it explored non-RIPC.15e17 Finally, 95 8 18e25 RCTs
were included.
From a methodological point of view (see online supplemen-
tary figure B), sample size was obtained to gain 90% power and
5% ά in four of the studies; randomisation was generated from
computers in four of them, while in three of them, the allocation
was performed in numbered containers. Moreover, in four
studies, patients, surgeons and doctors evaluating outcomes
were blinded; attrition bias was present in two of the six studies.
The Jadad scale (see online supplementary table A) showed
similar results.
Seven hundred and four patients were included (tables 1
and 2); most of them presented a multivessel disease, without an
important impairment of ejection fraction. RIPC protocol was
analogous in all studies consisting of three cycles of 5 min of
upper limb ischaemia with inflation to 200 mm Hg separated by
5-min periods of cuff deflation, except for one study in which
four cycles were performed.
Smd of troponin I and T release showed a significant small
decrease (0.36 (95% CI 0.62 to 0.09) (figure 2). This
difference held true after excluding the trials with cross-clamp
fibrillation, the study with off-pump CABG and studies using
a flurane as anaesthetic agent (0.41 (95% CI 0.69 to 0.12)),
0.38 (95% CI 0.70 to 0.07) and 0.37 (95% CI 0.63
to 0.12), respectively). A similar trend was also obtained for
patients with only multivessel disease (0.41 (95% CI 0.73
to 0.08)). (figure 3)
The trials evaluating postoperative creatinine reported a non-
significant reduction (0.02 (95% CI 0.09 to 0.13)). Moreover,
the length of in-hospital stay was not influenced by the kind of
treatment (wmd; 0.27 (95% CI 0.24 to 0.79)) (figures 4 and 5).
DISCUSSION
The present article represents the first attempt to perform
a pooled analysis about RIPC in CABG. RIPC reduced the
amount of cardiac enzyme release in patients undergoing CAGB,
while no differences in length of in-hospital stay and creatinine
values were reported.
Reduction in troponin release was demonstrated among
studies assessing both troponin T and I, and for patients with
surgical revascularisation of single vessel or with multivessel
disease. The restoration of blood supply to organs after a certain
period of no-flow ischaemia results in parenchymal damage
referred to as ischaemia-reperfusion injury.
In an attempt to shed light on the mechanisms underlying
cardioprotection, bench and bedside research focused on its
physiological substrate. The exact nature of signal transduction
from remote tissue to target organ remains to be elucidated.
However, three possible main mechanisms have been suggested,
which could variably contribute to the phenomena interacting
with each other and, therefore, not being mutually exclusive. The
abrogation of remotely induced cardioprotection with the
ganglion blocker hexamethonium, or the pre-treatment of
sensory nerves with capsaicin, suggested a neuronal pathway.26 27
However, Konstantinov et al28 demonstrated that RIPC can also
protect the denervated transplanted heart, suggesting a humoural
hypothesis. Several endogenous molecules have been implicated
(opioids, insulin, bradykinin, adenosine). These mediators gener-
ated in the organs remote from the heart enter the blood stream
and activate specific myocardial receptors that eventually recruit
intracellular pathways of cardioprotection.28 According to Batti-
paglia et al,29 besides the induction of changes in cardiomyocytes
that make them more resistant to ischaemia, RIPC may exert its
benefits through an additional humoural mechanism resulting in
a reduced platelet reactivity and thus, decreased thrombogenic
Figure 2 Standardised mean difference of troponin values. RIPC, remote ischaemic preconditioning.
Figure 3 Standardised mean difference of troponin values in patients with multivessel disease. RIPC, remote ischaemic preconditioning.
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burden. Eventually, RIPC showed a systemic anti-inflammatory
influence through suppression of pro-inflammatory gene expres-
sion activated by the cardiopulmonary bypass circuit and the
ischaemia-reperfusion injury.30 The many subcellular events
beyond humoural, neural and anti-inflammatory hypothesis are
not fully defined. Even though different intracellular signal
transduction mechanisms are recruited (such as, reactive oxygen
species, nitric oxide, and the mitochondrial KATP channel), the
ATP-sensitive potassium channel on the inner mitochondrial
membrane appears to be the critical one in promoting cell
survival.30 31
In the present study, the protective effect of RIPC on troponin
release was consistently independent from anaesthetic and
surgical technique. Continued evolution of cardioprotective
techniques, recognition that some anaesthetics can induce
cardioprotection, and changes in surgical methods have
confounded the translation of these results to modern practice.31
Some preliminary considerations around the RCTs included are
useful for interpretation of present results; the protocol
employed to administer remote upper arm preconditioning
showed substantial reproducibility in almost all trials.
Isofluorane, as anaesthetic,24 25 and cross-clamp fibrillation,32e34
although with different pathways, were demonstrated to
enhance a preconditioning protection in animal models with
a reduction in infarct size, thus questioning the positive effect of
RIPC in patients treated with these strategies. In the present
analysis, the troponin release was reduced in patients under-
going pre-conditioning after the inclusion or not of RCTs with
cross-clamp fibrillation and isofluorane as surgical and anaes-
thetic technique, respectively, stressing its value in different
operative settings.
However, these findings should be regarded with caution since
no clinical end-point was taken into account in the vast majority
of studies, and despite being limited by small sample size, no
reduction in length of in-hospital stay was noted. Myocardial
injury remains an important predictor of adverse outcome, and
the secondary inflammatory process contributes to post-
operative morbidity.4 To our knowledge, a randomised clinical
trial35 is recruiting patients to test the hypothesis that the
reduced troponin release demonstrated from our analysis will
translate into clinical benefits.
Although the bulk of research focuses on the heart as the
preconditioned organ, RIPC systemic anti-inflammatory influ-
ence proved to be protective against renal ischaemia-reperfusion
injury.3 11 Interestingly, our data do not support these previous
evidences. Possible explanations may be the exclusion criteria of
patients with renal disease from the original studies. These
populations would be at higher risk for postoperative kidney
injury, and therefore, may derive greater benefit from RIPC.
Other possible interfering factors could have been the intrave-
nous fluid administration during the postoperative period
(which carries a potential reduction of creatinine serum
concentrations), and the variation of glomerular filtration rate
caused by instability of perfusion rather than kidney damage.
Unfortunately, the original studies did not provide correction for
these potential biases.
The present article shares many limitations. First, all RCTs
consisted of a small sample size, a common feature of surgical
work,36 thus not allowing us to be conclusive, but stimulating
enough to trigger larger trial designs.35 Anyway, their quality
was acceptable according to international criteria, and no small-
study bias was assessed (online supplementary figures A and B).
We pooled all troponin values together according to smd, which,
as suggested from Cochrane, represents a useful tool to compare
the same clinical outcome measured with different scales.
Another limit is that none of the included studies was powered
to detect clinical differences evaluated in our analysis. Hetero-
geneity was in most cases mild; however, more conservative
random effects were exploited. The protocols were similar,
although one trial was with off-pump CABG and one with
fibrillation. Moreover, similar trends were found after exclusion
of studies with different surgical or anaesthetic protocols.
Figure 4 Weighted mean difference of creatinine release (mg/dl). RIPC, remote ischaemic preconditioning.
Figure 5 Weighted mean difference of in-hospital stay (days). RIPC, remote ischaemic preconditioning.
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In summary, we found that RIPC reduced troponin release in
patients undergoing CAGB. A surrogate clinical end-point
(length of in-hospital stay) and renal protection did not
demonstrate a significant decrease. Further research exploring
RIPC is needed to investigate whether the reduction of
myocardial injury observed impacts on clinical outcomes, and to
test renal protection through biomarkers insensitive to haemo-
dynamic effects.
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